The study, published in Nature Aging, found that FTL1 builds up in the hippocampus, the brain’s memory center, as mice get older. Too much of this protein disrupts brain function. Older mice with elevated FTL1 performed poorly on memory tasks. To confirm the link, scientists boosted FTL1 in younger mice.

To confirm the link, scientists boosted FTL1 in younger mice. These healthy mice quickly developed memory problems similar to older ones. But when scientists lowered FTL1 levels in aging mice, something remarkable happened: their memory improved to the level of much younger mice.

How FTL1 Affects the Brain

FTL1 helps store iron inside cells, but when it builds up in the brain, it disrupts how neurons generate and use energy. Neurons need energy to build and maintain connections, which are the pathways for learning and memory.

When FTL1 levels rise, neurons lose power. They cannot store information as effectively, leading to forgetfulness. Scientists also observed that older mice with high FTL1 had fewer connections between brain cells.

The team used advanced tools, including viruses and genetic methods, to change FTL1 levels. They then put mice through memory and learning challenges, such as solving mazes and recognizing objects. After reducing FTL1, older mice performed almost as well as young mice, proving that brain function could be restored.

The research also tested metabolism. Researchers discovered that when FTL1 levels rise, neurons struggle to produce enough energy. When they added NADH, a compound that helps with cell energy, memory problems improved. This suggests that targeting brain energy systems could be another way to help with memory loss reversal.

What This Means for Humans

While the results are exciting, the research is still at an early stage. The experiments were done only in male mice, and the human brain is far more complex. A treatment that works in mice may not work the same way in people.

Currently, there are no safe drugs that directly reduce FTL1 in humans. The methods used in the study involved genetic tools, not medicines. Researchers warn that it could take years before this discovery leads to new therapies.

Still, the findings are important because they focus on normal, age-related memory decline, not just diseases like Alzheimer’s. Almost everyone experiences some memory loss with age. By targeting FTL1, scientists may one day find a way to help a much larger group of people.

In the United States, between six and 12 million people over 65 live with mild cognitive impairment, a condition that often leads to dementia. About one-third of them develop Alzheimer’s within five years. For these individuals, new options for memory loss reversal could make a huge difference.

A New Direction in Brain Research

For decades, dementia research has centered on proteins like beta-amyloid and tau, which form clumps and tangles in the brain. The UCSF study adds a new angle by showing that iron-related proteins and energy systems may also be key to memory decline.

By focusing on FTL1, scientists are opening doors to treatments that could help almost everyone as they grow older—not just those with Alzheimer’s disease.

[Source]

The post Scientists Find Way to Reverse Memory Loss in Mice appeared first on Medical Journal Daily.

This research not only offers a new therapeutic avenue but also sheds light on the shared biological mechanisms that may link autism and epilepsy.

The Study

The study focused on the reticular thalamic nucleus (RT), a part of the brain responsible for processing sensory information. The researchers used mouse models of autism spectrum disorder (ASD), which were genetically modified with mutations in the CNTNAP2 gene, a gene strongly associated with autism.

These mice exhibited classic autism-like behaviors, including repetitive grooming, social withdrawal, hyperactivity, and an increased susceptibility to seizures. The scientists discovered that the neurons in their RT were overactive, a phenomenon linked to strong currents in what are known as T-type calcium channels.

The team then introduced Z944, also known as ulixacaltamide, a drug being studied as a potential treatment for seizure disorders. Z944 is a T-type calcium channel antagonist, meaning it works by blocking these specific currents.

The results were nothing short of remarkable. After administering just one dose of Z944, the mice showed a significant reversal of their autistic behaviors. Their repetitive grooming decreased, they became more socially interactive, and their hyperactivity was reduced.

The drug appeared to “quiet” the overactive RT region, leading to a profound change in their behavior. This finding was further validated when the researchers genetically modified the mice to have increased activity in the RT, causing the autistic behaviors to return.

This suggests that Z944’s ability to suppress this specific brain region is the key to its therapeutic effect.

The Overlap Between Autism and Epilepsy

The findings of this study provide crucial evidence for a long-suspected connection between autism and epilepsy. Autistic individuals are up to 30 times more likely to develop epilepsy than the general population. This high comorbidity has led experts to believe that the two conditions may share underlying biological mechanisms, and this new research strongly supports that theory.

The study suggests that the same overactive neural circuits and channels in the RT that contribute to autistic symptoms may also be a factor in seizure activity. This potential overlap not only explains why the conditions often coexist but also highlights a promising new target for treatment that could address both simultaneously.

While the prospect of a single-dose treatment is exciting, the researchers are quick to emphasize that these findings are still preliminary and based on animal models.

It remains unclear how these results will translate to humans. However, the study provides a critical framework for future research. The scientists note that the next steps should focus on understanding how the RT’s influence on the broader brain circuitry affects the full spectrum of ASD behaviors.

This knowledge could pave the way for highly precise, circuit-specific interventions tailored to the needs of individuals with autism. As Z944 continues its clinical trials for epilepsy, its potential as a dual-purpose drug for both epilepsy and autism remains a captivating possibility that could fundamentally change the lives of millions.

[Source]

The post New Seizure Drug Shows Promise in Reversing Autism Symptoms in Mice appeared first on Medical Journal Daily.

Rewriting Gene Activity in the Diseased Brain

Alzheimer’s disease disrupts how genes operate in brain cells. To understand this better, scientists first mapped the patterns of gene activity in individual neurons and support cells (called glia) from brains affected by the disease. This process, known as gene expression profiling, shows which genes are active or dormant. The researchers then searched for drugs that could flip those patterns back toward normal.

They turned to a large public database called the Connectivity Map, which catalogs how thousands of drugs affect gene activity in human cells. Out of 1,300 drugs, just 10 reversed Alzheimer’s-linked gene patterns across different brain cell types, and only five were already approved by the U.S. Food and Drug Administration.

Using medical records from over 1.4 million patients across California’s university hospitals, the researchers looked for any real-world signs that those drugs might help prevent Alzheimer’s. The records showed that people who had taken some of these medications, mostly for cancer, appeared less likely to develop the disease later on.

Targeting Two Cell Types with a Two-Drug Combo

From this shortlist, the team selected two drugs: letrozole, typically used to treat breast cancer, and irinotecan, used against colon and lung cancers. They believed each drug would target a different cell type — letrozole for neurons and irinotecan for glia — like a two-part key unlocking different doors in the brain.

When given to mice with advanced Alzheimer’s-like symptoms, the drug duo had striking effects. It stopped further damage, reduced toxic protein buildup, and even restored the animals’ ability to remember how to navigate mazes. Memory, in this case, was not just protected, it was brought back from the edge.

The researchers compare the process to rewiring a city after a blackout, where different crews work on separate grid sections, but the lights only come back when efforts are synchronized. Similarly, targeting both neurons and glia may be the missing link that single-drug strategies have overlooked.

A Possible Turning Point for Alzheimer’s Treatment

“This study opens a new door using drugs we already have,” said lead researcher Yadong Huang. His team emphasizes that although results in mice are promising, human trials are essential to confirm safety and effectiveness.

Letrozole and irinotecan, though widely used in cancer treatment, can come with serious side effects. If repurposed for Alzheimer’s, their doses and delivery methods will likely need major adjustments. The upside? Since the drugs are already approved, clinical trials could begin sooner than if researchers had to start from scratch.

With over 55 million people living with Alzheimer’s worldwide and that number set to double in the next two decades.

As co-author Marina Sirota puts it, “When two completely different kinds of data — from cells and from real patients — lead to the same drug, and it works in a model of the disease, we may finally be onto something.”

[Source]

The post Two Cancer Drugs Show Surprising Potential Against Alzheimer’s in Early Tests appeared first on Medical Journal Daily.

Rinri Therapeutics, a biotech company born from years of academic research at the University of Sheffield, has been granted approval to begin the world’s first human trial of a cell therapy designed to restore hearing by repairing the auditory nerve itself. Called Rincell-1, the treatment aims to regenerate nerve cells in the inner ear that are essential for transmitting sound signals to the brain—cells that no current treatment can replace.

A New Approach to Hearing Loss

Most people are familiar with hearing loss that comes from damaged hair cells in the inner ear. But in neural hearing loss—seen in conditions like age-related hearing decline (presbycusis) and auditory neuropathy spectrum disorder (ANSD)—the issue lies deeper, in the nerve fibers that connect the ear to the brain. Cochlear implants can help, but only if the auditory nerve is still functional.

Rincell-1 offers something radically new. It uses lab-grown precursor cells—called otic neural progenitor cells—that are designed to mature into working auditory neurons after being delivered directly into the cochlea during cochlear implant surgery. In essence, it’s like rewiring a frayed cable at its core, not just boosting the signal.

“Instead of just amplifying or rerouting sound, we’re aiming to rebuild the broken connection,” said Professor Marcelo Rivolta, the therapy’s lead scientist and co-founder of Rinri Therapeutics.

Trial Details: Who’s In and What’s Next

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a Phase I/IIa trial, which will be conducted at three of the country’s top hearing research centers. The trial will involve 20 adult participants: ten diagnosed with auditory neuropathy spectrum disorder (ANSD) and ten with advanced age-related hearing loss. In each group, half will receive both a cochlear implant and the experimental treatment, Rincell-1, while the rest will be fitted with the implant only.

This isn’t just about seeing whether the treatment works—it’s first about safety. But researchers will also be looking for early signs that the therapy helps regenerate nerve activity. They’ll use real-time data from a monitoring system built into the cochlear implants, as well as speech perception tests and patient feedback.

Within a year of starting, the team expects to gather proof-of-concept data—an early indicator of whether this therapy could become a viable treatment.

Opening a Door Previously Sealed Shut

The auditory nerve endings are buried deep within the skull, protected by bone and difficult to reach. Traditional surgery would require extensive drilling—something too risky and painful for a routine procedure.

Now, thanks to collaborative research across universities in the UK, Canada, and Sweden, a less invasive method has been developed. Described in Nature Scientific Reports, the new approach uses a natural membrane in the inner ear called the round window as a gateway. Through this access point, surgeons can deliver the regenerative cells directly to the site of damage with far less trauma.

“It’s like slipping a message through a mail slot instead of breaking down the front door,” said Professor Doug Hartley, Rinri’s Chief Medical Officer and one of the architects of the new procedure.

Why This Trial Matters

Neural hearing loss impacts more than 100 million people globally, and that number is projected to grow as populations age. Yet treatments have lagged behind, partly because regenerating nerve tissue in the ear was once considered impossible. Rincell-1 is the first attempt to not just manage symptoms but actually change the trajectory of the disease.

The therapy was developed using Rinri’s OSPREY™ platform—a method for producing ready-to-use cell therapies that don’t rely on patient-specific donor cells. That means, if successful, Rincell-1 could one day be available “off-the-shelf,” making it more accessible and affordable than personalized regenerative therapies.

For now, all eyes are on this first trial. It’s the scientific equivalent of planting a seed in long-frozen soil—no guarantees, but a real chance that something once thought lost could grow again.

[Source: 1,2]

The post First Human Trial of Regenerative Cell Therapy Targets Age-Related and Neural Hearing Loss appeared first on Medical Journal Daily.

Dental Pulp Cells Can Repair Tissues Beyond the Mouth

Scientists around the world are culturing and testing dental pulp cells in the lab. At CSIRO’s Stem Cell Centre in Australia, for instance, researchers examine cultured stem‑cell samples under high‑resolution microscopes.

In the lab, DPSCs self‑renew and proliferate rapidly. Studies show that when given the right signals, DPSCs will lay down collagen and calcium to form bone or cartilage matrix and even beat and contract like muscle.

Compared with bone‑marrow stem cells, DPSCs often build mineralized (bone) tissue more quickly. In engineered joint grafts they can produce cartilage tissue in vitro. In one animal study, combining human dental pulp cells with a scaffold led to significantly more new bone growth than a scaffold alone.

Such findings give hope that wisdom‑tooth cells could one day aid in healing fractures, repairing jawbones after tumor surgery, or rebuilding degenerated cartilage in arthritic joints. Each year millions of wisdom teeth are removed and usually discarded. In the United States alone an estimated ten million molars are extracted annually.

Tooth Banking and the Future of Personalized Medicine

A growing number of biotech startups and dental clinics now offer “tooth banking” – preserving a patient’s pulp cells for possible future use. The process of collecting dental pulp stem cells begins immediately after the tooth is removed.

The extracted wisdom tooth is placed in a sterile container and transported under cold conditions to a laboratory. There, specialists extract the pulp tissue and typically freeze the stem cells within a day to preserve their viability.

Proponents note that banking one’s own DPSCs eliminates concerns about immune rejection later, and the upfront cost (comparable to cord‑blood banking) could pay off if personalized therapies are needed decades down the line.

Clinics partner with oral surgeons to harvest molars that would otherwise be discarded, turning “trash” into a long‑term biological asset. Early experiments hint at a wide range of potential therapies.

For example, cardiologists have tested injections of dental‑pulp cell secretions in rodents with heart failure, and observed improved cardiac function – suggesting that a patient’s own wisdom‑tooth cells might one day help mend a damaged heart.

In neurological studies, DPSC transplants into Alzheimer’s‑model mice produced measurable improvements in memory and brain pathology.

It can generate dopamine‑producing neurons in culture, and rodent models of Parkinson’s disease showed motor improvements with dental stem cell therapy.

DPSCs appear to secrete a cocktail of growth factors that protect nerves, reduce inflammation and even help clear toxic proteins in the brain. Outside the nervous system, laboratories report that dental pulp cells readily become osteoblast‑like and build bone in 3D scaffolds, making them promising for filling bone defects.

More Work Is Needed to Prove Safety and Efficacy

As the evidence grows, investigators are planning clinical trials of dental pulp therapies. Early stem‑cell implants (using embryonic stem cells) in Parkinson’s patients have already demonstrated that new dopamine neurons can survive and function in humans. Using DPSCs instead could avoid ethical controversies and reduce immune risk.

However, experts caution that more work is needed. Transplanted cells must be shown safe (without forming tumors) and effective in people. Scientists at universities and institutes worldwide – for example at the University of the Basque Country in Spain – continue refining protocols to turn tooth pulp into therapy. “These are easily accessible human stem cells for nerve tissue engineering,” researchers note.

They argue that routinely preserving wisdom teeth now could create a personalized “biobank” of one’s own stem cells, offering future regenerative treatments without the wait for a perfect donor match. Wisdom teeth may have been viewed as nuisances, but modern research is recasting them as biological treasure.

Before tossing those extracted molars, patients might consider the hidden value inside. In the coming years, therapies for bone injuries, neurological diseases or heart disease may indeed spring from the “medical gold” locked in wisdom tooth pulp.

[Source: 1,2]

The post “Medical Gold” From Extracted Wisdom Teeth Are Being Used to Treat a Range of Diseases appeared first on Medical Journal Daily.

Microparticles designed to release vaccines at set times

The research team’s approach involves packaging multiple doses of a vaccine into a single injection, using specially engineered microparticles that release each dose at a pre-programmed time. Instead of returning weeks or months later for a booster, a child could receive the entire course during one clinic visit.

The microparticles used in this vaccine system are built from a material group known as polyanhydrides. These particles are engineered as small, enclosed units that break down slowly once inside the body. As they degrade, they release the vaccine at specific intervals. The timing of this release depends on how the material is structured at the molecular level.

Mouse studies show immune response from delayed release

The team, led by researchers Ana Jaklenec and Robert Langer, recently demonstrated this timed delivery system in mice. The experiment involved two doses of a diphtheria vaccine: one released immediately and the second programmed to release two weeks later. The immune response in the mice mirrored what is typically seen when two separate injections are given weeks apart.

A major technical challenge was ensuring that the vaccine remains stable inside the microparticles during the delay between injection and release.

Traditional polymers like PLGA, which have been used for similar delivery systems, tend to create an acidic environment as they break down. This can damage sensitive biological materials like vaccines. The team chose polyanhydrides because they break down more slowly and produce less acidity, making them more suitable for carrying live or fragile antigens.

To identify the most effective versions of these materials, the team created a library of 23 polyanhydride types, each with slight variations in chemical makeup. They used a method called SEAL — stamped assembly of polymer layers — to form the particles and test their durability, sealing strength, and release performance.

After narrowing the list to the six most promising candidates, they tested them in mice.

Machine learning guides material design for timed release

To improve their material selection process, the researchers also developed a machine learning model. This algorithm predicted how changes in polymer composition would affect release timing, allowing them to screen hundreds of potential combinations virtually before testing a few in the lab.

Although still in early stages, this technology offers a possible shift in how vaccines are administered. If scaled successfully, it could benefit populations where returning for a second or third dose is a logistical challenge.

Clinics in rural areas, mobile vaccination units, and emergency response teams could all use a system that delivers complete protection in a single shot.

Potential for use in childhood vaccines and other treatments

Beyond childhood vaccines, the same method might be used to deliver other medications that require controlled timing, including hormone therapies or certain cancer treatments. For now, the immediate focus is on extending the interval between dose releases and testing the approach with other diseases like polio and measles.

This new form of vaccine delivery may not eliminate all barriers to global immunization, but it offers a practical way to reach more people with fewer resources.

By reducing the need for multiple appointments, it could help healthcare workers deliver lifesaving treatments more efficiently, especially in places where time and access are in short supply.

[Source]

The post How One Injection Could Deliver Multiple Vaccine Doses Ending the Need for Booster Shots appeared first on Medical Journal Daily.

The therapy, known as zimislecel, is made from lab-grown islet cells developed from pluripotent stem cells. These engineered cells are designed to replace the insulin-producing beta cells destroyed in people with type 1 diabetes. In the study, the cells were delivered into patients’ livers through the portal vein and began producing insulin naturally.

A Small but Promising Study

The trial, conducted by Vertex Pharmaceuticals, involved 14 participants. All had type 1 diabetes with no measurable C-peptide at baseline, indicating an absence of natural insulin production. Of the 12 individuals who received the complete zimislecel infusion, 10 no longer required insulin a year later.

Each participant showed signs of functioning islet cells and avoided any serious hypoglycemic incidents during the last nine months of follow-up.

The trial results, presented at the 2025 American Diabetes Association conference and published in The New England Journal of Medicine, point to zimislecel as a possible treatment route for patients with difficult-to-manage or advanced type 1 diabetes.

Restoring Natural Insulin Production

Participants in the trial had previously lived with hypoglycemic unawareness, a complication where the body no longer warns of dangerously low blood sugar levels. This can result in sudden fainting, seizures, or even death. Following treatment with a full dose of zimislecel, none of the 12 participants experienced additional episodes of dangerously low blood sugar.

The infusion triggered insulin production within weeks. Patients began reducing their insulin requirements around the three-month mark, with most stopping entirely by month six. All participants spent more than 70 percent of their time in the recommended blood glucose range between 70 and 180 mg/dL.

Amanda Smith described the experience as a return to normalcy. She joined the study after years of managing her blood sugar around the clock. The result, she said, has been “a whole new life,” though she remains on immunosuppressive medication to preserve the function of the transplanted cells.

Managing the Risks of Immune Suppression

To prevent the body from rejecting the implanted cells, all participants were placed on immunosuppressive drugs. While these medications were chosen to avoid corticosteroids, they still carry risks.

Three participants developed neutropenia, a condition that weakens the immune system, and two died during the study’s follow-up period. One death was linked to fungal meningitis, and the other to worsening dementia. Both patients had underlying medical conditions before entering the trial.

Researchers acknowledged these risks and emphasized the importance of long-term monitoring. “We’re still learning what this means over the course of many years,” said Dr. Trevor Reichman, pancreas and islet transplant program director at University Health Network in Toronto and lead author of the study.

Built on Decades of Research

Zimislecel is the result of over two decades of work, beginning with a Harvard lab led by Dr. Doug Melton. Motivated by his children’s diagnoses with type 1 diabetes, Dr. Melton focused his career on transforming stem cells into functioning islet cells. After finding a reliable method, the research was taken forward by Vertex Pharmaceuticals for clinical development.

The trial was limited to patients with severe diabetes who could not manage their condition effectively with current therapies. Enrollment was selective, and some eligible patients declined participation after learning they would need immunosuppressive drugs for life.

A New Option for a High-Risk Group

Dr. Irl Hirsch, a diabetes expert from the University of Washington who was not affiliated with the research, observed that the therapy may serve a critical role for patients at high risk of sudden and severe glucose drops. He added that for patients with well-managed type 1 diabetes, the trade-offs may not be worth the risk until safer long-term data become available.

Zimislecel is not yet approved for public use, and pricing has not been disclosed. Vertex plans to continue testing zimislecel in future studies and aims to submit its findings to the U.S. Food and Drug Administration for review.

For patients like Amanda Smith, the therapy represents a shift in what diabetes care could look like. Though not a cure, zimislecel shows that it may be possible to restore the body’s own insulin production with a single intervention—at least for those who need it most.

[Source]

The post Type 1 Diabetes Patients Off Insulin After a Single Dose of Experimental Manufactured Stem Cells appeared first on Medical Journal Daily.

This failure in cellular housekeeping, researchers say, could be more than a side effect. It might be a core issue in the development of autism and possibly other brain-related disorders such as schizophrenia.

The Search for a Consistent Model

Autism spectrum disorder is known to be influenced by genetics, but the range of mutations linked to the condition has made it difficult to study. Each variation may affect a different biological pathway, making it challenging to find patterns.

In an effort to make sense of autism’s genetic complexity, neuroscientist Takumi Toru and his team dedicated over ten years to developing a uniform research system.

They turned to mouse embryonic stem cells—versatile cells capable of transforming into virtually any cell type—to build a foundation for studying autism-linked mutations in a controlled and repeatable way.

By combining this flexibility with CRISPR gene editing, the team created 63 lines of stem cells—each carrying one of the autism-linked genetic changes found in human studies.

These stem cells can be turned into neurons or even grown into mice, allowing researchers to study how each mutation plays out in brain development and behavior.

A Closer Look at Neuronal Behavior

To test the new models, the researchers grew neurons from 12 of the 63 cell lines and studied their genetic activity in detail. One pattern stood out. A number of the neurons had unusually low levels of a gene called Upf3b, which helps identify and eliminate misshapen or excess proteins.

Protein production in neurons is a high-stakes process. These cells make proteins locally in their extensions and connections, not just in the cell body. This allows them to respond quickly, but it also means that any quality control failure could cause local dysfunction.

“When we looked at the data, it was clear that something was wrong with the way these neurons were managing their proteins,” said a researcher from the Kobe team. “The same types of problems appeared again and again across different genetic models.”

Shared Features Across Brain Disorders

The finding may not be limited to autism. Many of the genetic mutations studied in the Kobe models are also associated with conditions like bipolar disorder and schizophrenia. These disorders share some symptoms with autism, such as difficulties with communication or sensory processing, though they differ in onset and severity.

If a common failure in protein regulation is involved in all three, it could point to a broader mechanism that affects how the brain develops and maintains its functions.

This idea is supported by previous findings from other research teams, which have noticed similar problems in protein handling in postmortem brain tissue from people with psychiatric disorders. But until now, there has not been a controlled way to study these issues across multiple mutations in a single system.

From Cell Lines to Practical Research

The 63 mouse stem cell lines developed by the Kobe team are now available for other researchers to use. This means scientists working in drug development or brain imaging can begin testing whether interventions that improve protein quality control also reduce traits associated with autism.

In one experiment at Kobe, researchers grew full adult mice from the engineered cells. Some showed repetitive behavior patterns, such as touching their whiskers to the same spot in their enclosure over and over again. Follow-up analysis of their neurons showed a buildup of malformed proteins, suggesting a possible connection between this microscopic dysfunction and outward behavior.

The hope is that focusing on these shared cellular weaknesses may help simplify autism research by highlighting common vulnerabilities, rather than trying to track the effects of every individual mutation.

Takumi and his team are careful to note that this approach does not explain all aspects of autism, which remains a complex and highly variable condition. But identifying a failure in protein cleanup as a repeatable feature is a step toward understanding what makes the condition appear across different people with different genetic backgrounds.

Looking Ahead

This work marks a shift in autism research from tracking genes individually to understanding the cellular systems they affect. If future studies confirm that protein regulation is a weak point in early brain development, then therapies could be designed to target this process—potentially offering a new approach for early intervention.

For now, the Kobe stem cell bank stands as a shared platform for scientists worldwide to explore the biology of autism and related disorders using a consistent and flexible set of tools.

[Source]

The post Mouse Stem Cell Models Reveal a Surprising Link Between Faulty Protein Control and Autism Traits appeared first on Medical Journal Daily.

SPVX02 is formulated using the company’s proprietary StablevaX™ technology, which enables existing vaccines to remain stable at room temperature. In preclinical tests, the vaccine retained its efficacy after undergoing three cycles of temperature fluctuations between -20°C and 40°C. This kind of thermal resilience is rare among biologics and critical to improving vaccine access in low-resource or remote settings.

Tackling Vaccine Waste Through Thermostability

This fridge-free vaccine aims to address a well-documented challenge in global health: vaccine loss due to cold chain failures. According to the World Health Organization, around 50% of vaccines are wasted annually, often because they are compromised during transport or storage. Most conventional vaccines require strict temperature control, typically between 2°C and 8°C. Some even demand sub-zero storage.

SPVX02 has an 18-month shelf life at room temperature, which not only reduces the logistical burden but also minimizes dependence on refrigeration infrastructure. This has significant implications for vaccination campaigns in areas with unreliable electricity or limited refrigeration capacity.

Stablepharma’s innovation could help reduce these inefficiencies, making immunization programs more resilient, particularly during emergencies or in regions with poor access to cold-chain networks.

Government and EU-Backed Research

The current trial is funded through a combination of UK government support and European Union research initiatives. Funding support for the project has come from UK-based innovation bodies, including Innovate UK and NIHR, which back promising health technologies.

In February 2025, the company was awarded €2.5 million from the European Innovation Council Accelerator, following an earlier €50,000 grant from the Horizon Europe program in 2021.

These grants are part of broader efforts to advance vaccine innovation and improve preparedness for future health emergencies.

Professor Saul Faust, Director of the NIHR Southampton Clinical Research Facility, is leading the trial. He emphasized the significance of testing thermostable vaccines in human subjects, noting that it marks a turning point in vaccine delivery research.

Expanding the Platform Beyond SPVX02

Stablepharma views SPVX02 as just the beginning. The company has identified up to 60 existing vaccines that could be reformulated using the StablevaX™ platform. These include vaccines that are currently restricted by cold-chain requirements, such as those for polio, hepatitis, and measles.

Chief Development Officer Dr Karen O’Hanlon stated that SPVX02 demonstrates how thermostable vaccines can be produced at scale under Good Manufacturing Practice (GMP) conditions, paving the way for mass distribution without relying on refrigeration.

Should the trial outcomes remain positive, the company plans to launch SPVX02 commercially by 2027. The company believes that thermostable vaccines could play a key role in improving global vaccine coverage and reducing barriers to access.

Implications for Global Health

Fridge-free vaccines offer a practical solution to a persistent problem in immunization delivery. Their ability to remain effective outside a controlled environment could transform how vaccines are transported, stored, and administered—especially in remote, conflict-affected, or resource-poor regions.

If successful, the SPVX02 trial could validate a scalable model that significantly reduces vaccine spoilage and extends immunization reach.

As the trial progresses, researchers and health policymakers worldwide will be watching closely. The outcome may not only affect future vaccine logistics but also inform the next generation of biologic formulation technologies.

[Source]

The post Stablepharma Tests Fridge-Free Vaccine That Could Help Cut Global Wastage appeared first on Medical Journal Daily.

Developed by the British biotech firm Xgenera alongside researchers from the University of Southampton, the test examines microRNA—fragments of genetic material linked to cancer activity. These markers are then processed using AI to detect if cancer is present and where in the body it may be.

A Blood Sample Instead of a Biopsy

For many cancers, diagnosis still depends on methods like colonoscopies or biopsies, which can be stressful and time-consuming. This new approach requires just a small vial of blood. Once analyzed, the AI system can flag the presence of cancer cells with a reported accuracy of over 99%.

The test targets a wide range of cancers including bowel, breast, lung, prostate, pancreatic, and others. This broad reach is one of the reasons it’s being considered as a future screening tool.

Who’s Part of the Trial and What They Hope to Prove

Roughly 8,000 people will take part in the NHS trial—some already showing signs of illness, others not. The idea is to measure the test’s performance across a variety of conditions and confirm how it might work if used more broadly in routine care.

To support its development, the UK government has allocated £2.4 million toward the project. Secretary Wes Streeting, who himself has undergone cancer treatment in the past, early and accurate detection is essential if survival rates are to improve. He called this initiative a step toward speeding up diagnosis and easing the burden on NHS services.

Making It Fast, Scalable, and Cost-Effective

One of the biggest challenges in cancer care is catching the disease early without overwhelming health systems. Known as miONCO-Dx, the blood test could provide a practical alternative to conventional cancer detection methods. It only needs 10 to 15 drops of blood and costs far less than current diagnostic tools—estimated between £120 and £300 per test.

Andy Shapanis, who leads Xgenera, says the real goal is to develop something that could work at a national level. “We’re looking at a tool that can operate at scale without sacrificing accuracy,” he explained. In early tests, the technology performed equally well in detecting early- and late-stage cancers.

Building the Foundation for National Cancer Screening

If the full trial goes well, this test might one day be offered as part of standard NHS checkups. That could significantly cut down on diagnostic delays and reduce the need for more invasive investigations.

Bowel cancer, for example, is among the illnesses this test could detect. While it’s the third most common cancer in the UK, it often goes unnoticed until it’s too late. When diagnosed in its early stages, bowel cancer has a survival rate close to 90%. But if it’s detected late, that rate can fall dramatically to around 10%.

Research and further development will continue at the newly renamed BowelBabe Laboratory at the Francis Crick Institute in London. The facility honors the legacy of Dame Deborah James, who died of bowel cancer in 2022 and raised millions for research before her passing.

This project is also part of a wider national plan to modernize cancer care and make the latest detection technologies more accessible to patients across the UK. As Professor Lucy Chappell of the National Institute for Health and Care Research put it, tools like this bring us closer to faster, easier, and more accurate diagnoses—just when patients need it most.

[Source: 1,2]

The post NHS Trials Blood Test to Detect 12 Common Cancers with Over 99% Accuracy appeared first on Medical Journal Daily.